


of the artificial sequence. This objection is somewhat incomprehensible since the artificial sequence as defined in the Sequence Listing simply is an artificial peptide of the particular amino acids recited in the sequence and need not be from any particular source, genetic or otherwise. As stated in the specification of the present application, the present peptides are artificial peptides which are utilized as therapeutic compounds in the treatment of impaired behavioral and interpersonal disorders.

In light of the above, Applicants' counsel telephoned the Sequence Listing office and was told that a description that the present sequences as peptide sequences that were "designed to achieve therapeutic effects in mammals" would be sufficient to overcome the objection, and thus Applicants have amended the sequence listing in this manner and have made other minor changes as appropriate.

Accordingly, Applicants submit that the present application is now in compliance with Sequence Listing requirements, and should there be any additional questions regarding the Sequence Listing, Applicants request that the sequence examiner contact the undersigned counsel by telephone to more efficiently resolve any other outstanding questions.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "B. Aaron Schulman", is written over a horizontal line.

B. Aaron Schulman
Registration No. 31,877

May 2, 2002

LARSON & TAYLOR, PLC
1199 North Fairfax Street, Suite 900
Alexandria, Virginia 22314
(703) 739-4900